References
- Fessel WJ. Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms: the high prevalence in black women. Arch Intern Med 1974: 134(6): 1027–35
- Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979: 66(2): 210–5
- Wasner CK, Fries JF. Treatment decisions in systemic lupus erythematosus. Arthritis Rheum 1980: 23(3): 283–6
- Jarrett MP, Sablay LB, Walter L, et al. The effect of continuous normalization of serum hemolytic complement on the course of lupus nephritis: a five year prospective study. Am J Med 1981:70(5): 1067–72
- Ballou SP, Kushner I. Lupus patients who lack detectable anti-DNA: clinical features and survival. Arthritis Rheum 1982: 25(9): 1126–9
- Mahajan SK, Ordonez NG, Feitelson PJ, et al. Lupus nephropathy without clinical renal involvement. Medicine (Baltimore) 1977:56(6): 493–501
- Ballou SP, Khan MA, Koshner I. Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation. J Rheumatol 1985: 12(5): 944–8
- Kimberly RP, Lockshin MD, Sherman RL, et al. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 1981:70(4): 817–24
- Deal CL. Pulse methylprednisolone therapy: a review of serious side effects. (Abstr) Clin Res 1985: 33(4): 917A
- Balow JE, Austin HA 3d, Mnenz LR, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984: 311(8): 491–5
- Whiting-O'Keefe Q, Henke JE, Sbearn MA, et al. The information content from renal biopsy in systemic lupus erythematosus: stepwise linear regression analysis. Ann Intern Med 1982: 96(6 Pt 1): 718–23
- Austin HA 3d, Mnenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983:75(3): 382–91
- Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984: 311(24): 1528–33
- Steinberg AD. The treatment of lupus nephritis. Kidney Int 1986: 30: 769–87
- Dinant HJ, Decker JL, Klippel JH, et al. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982: 96(6 Pt 1): 728–36
- Sessioms SL, Kovarsky J. Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus. Clin Exp Rheumatol 1984: 2: 247–51
- Wei N, Klippel JH, Huston DP, et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983: 1(8314–5): 17–22
- Agnello V, Pariser K, Gell J, et al. Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement. J Rheumatol 1983: 10(5): 682–7
- Tozman EC, Urowitz MB, Gladman DD. Systemic lupus erythematosus and pregnancy. J Rheumatol 1980:7(5): 624–32
- Sergent JS, Lockshin MD, Klempner MS, et al. Central nervous system disease in systemic lupus erythematosus: therapy and prognosis. Am J Med 1975: 58(5): 644–54